AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36717833 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine-tension-type-index
Number of subjects: 253
Study 36717894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS
Number of subjects: 4
Study 36717894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mA cathodal tDCS
Number of subjects: 4
Study 36717894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS
Number of subjects: 4
Study 36717894 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 4
Study 36717911 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration and circadian misalignment
Number of subjects: 120
Study 36717911 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function and hedonic eating tendencies
Number of subjects: 120
Study 36718018 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib (5.6 mg/kg IV days 1, 4, 8, and 11) in combination with Carboplatin (AUC 4 IV day 1) and Gemcitabine (1000 mg/m2 IV days 1 and 8)
Number of subjects: 26
Study 36718142 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg (days 1 and 8) + Cetuximab 250 mg/m2
Number of subjects: 43
Study 36718142 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab + Cetuximab + Chemotherapy
Number of subjects: 43
Study 36718176 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 69
Study 36718176 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching (PC)
Number of subjects: 69
Study 36718176 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF)
Number of subjects: 69
Study 36718176 — intervention group
Group type: EXPERIMENTAL
Intervention: EUC plus both PC and PF
Number of subjects: 69
Study 36718400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Analgesia (HAS)
Number of subjects: 18
Study 36718400 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 18
Study 36718400 — intervention group
Group type: COMPARATOR
Intervention: rest-testing
Number of subjects: 18
Study 36718624 — intervention group
Group type: EXPERIMENTAL
Intervention: Senaparib (oral, 100 mg daily in 3-week cycles)
Number of subjects: 39
Study 36718638 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRY-371797 400 mg or 100 mg twice daily for 48 weeks
Number of subjects: 12
Study 36718646 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-Patient Testing (NPT)
Number of subjects: 656
Study 36718646 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care Testing
Number of subjects: 656
Study 36718763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pi10 (standardized airway wall thickness)
Number of subjects: 0
Study 36718763 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 0
Study 36718994 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical conditioning with verbal suggestion
Number of subjects: 68
Study 36718994 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion alone
Number of subjects: 68
Study 36718994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham electrodes as placebo treatments
Number of subjects: 68
Study 36718994 — intervention group
Group type: COMPARATOR
Intervention: Topical gels as placebo treatments
Number of subjects: 68
Study 36719104 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily + metronidazole 400 mg three times daily)
Number of subjects: 268
Study 36719104 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily)
Number of subjects: 268
Study 36719158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 91
Study 36719158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 36719160 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 98
Study 36719160 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 36719293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using contrast-enhanced CT
Number of subjects: 523
Study 36719293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using MRI
Number of subjects: 523
Study 36719293 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using CT
Number of subjects: 523
Study 36719293 — intervention group
Group type: COMPARATOR
Intervention: Patients with CSPH (n=213)
Number of subjects: 523
Study 36719293 — intervention group
Group type: COMPARATOR
Intervention: Patients without CSPH (n=310)
Number of subjects: 523
Study 36719367 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPPWRQoL instrument
Number of subjects: 25
Study 36719367 — intervention group
Group type: COMPARATOR
Intervention: WRQoL Scale
Number of subjects: 25
Study 36719506 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-aPDT with an 810 nm diode laser
Number of subjects: 24
Study 36719506 — intervention group
Group type: COMPARATOR
Intervention: FMUD (control)
Number of subjects: 24
Study 36719566 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg every 2 weeks for children; 1.0 mg/kg every 4 weeks for adults)
Number of subjects: 24
Study 36719566 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab self-administration
Number of subjects: 24
Study 36719566 — intervention group
Group type: COMPARATOR
Intervention: Burosumab administered by a healthcare professional (HCP)
Number of subjects: 24
Study 36719704 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced triage implemented in the prospective phase (n=547)
Number of subjects: 1642
Study 36719704 — intervention group
Group type: COMPARATOR
Intervention: Retrospective phase (n=1095)
Number of subjects: 1642
Study 36719715 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Vita HF platform (telemonitoring of blood pressure, pulse, and weight)
Number of subjects: 150
Study 36719715 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal health record usage
Number of subjects: 150
Study 36719720 — intervention group
Group type: EXPERIMENTAL
Intervention: Amazon Alexa (digital screening)
Number of subjects: 52
Study 36719720 — intervention group
Group type: COMPARATOR
Intervention: Research coordinators (manual screening)
Number of subjects: 52
Study 36719721 — intervention group
Group type: EXPERIMENTAL
Intervention: SiD decision aid
Number of subjects: 500
Study 36719721 — intervention group
Group type: COMPARATOR
Intervention: Control website
Number of subjects: 500
Study 36719732 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaysian Geriatric Patients' Hospital Foodservice Protocol (MYGERYFS)
Number of subjects: 233
Study 36719732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 233
Study 36719749 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-LAG-3+anti-PD-1
Number of subjects: 40
Study 36719784 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Number of subjects: 0
Study 36719885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary physiotherapy (PPT) - six sessions with breathing exercises and airway clearance techniques
Number of subjects: 40
Study 36719885 — intervention group
Group type: COMPARATOR
Intervention: Basic care
Number of subjects: 40
Study 36719885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary physiotherapy (PPT)
Number of subjects: 40
Study 36719885 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary physiotherapy (PPT) and Basic care
Number of subjects: 40
Study 36719886 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-MCT+CR (n = 118)
Number of subjects: 240
Study 36719886 — intervention group
Group type: COMPARATOR
Intervention: Usual CR alone (n = 122)
Number of subjects: 240
Study 36720083 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once-daily for 3 years
Number of subjects: 682
Study 36720083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682
Study 36720083 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 682
Study 36720090 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa plus venetoclax
Number of subjects: 23
Study 36720090 — intervention group
Group type: COMPARATOR
Intervention: Eftozanermin alfa monotherapy
Number of subjects: 23
Study 36720089 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete severe acute respiratory syndrome coronavirus 2 vaccination course
Number of subjects: 613
Study 36720089 — intervention group
Group type: COMPARATOR
Intervention: Prevaccination phase (February 27, 2020-November 30, 2020)
Number of subjects: 613
Study 36720089 — intervention group
Group type: COMPARATOR
Intervention: Alpha-Delta phase (December 1, 2020-December 14, 2021)
Number of subjects: 613
Study 36720089 — intervention group
Group type: COMPARATOR
Intervention: Omicron phase (December 15, 2021-January 31, 2022)
Number of subjects: 613
Study 36720132 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal CPR
Number of subjects: 160
Study 36720132 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 160
Study 36720133 — intervention group
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa prophylaxis (50 IU/kg) for 52 weeks in group A
Number of subjects: 159
Study 36720133 — intervention group
Group type: COMPARATOR
Intervention: Efanesoctocog alfa on-demand treatment for 26 weeks followed by prophylaxis for 26 weeks in group B
Number of subjects: 159
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisearch Multilocation Task (MSML)
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack Delay Task (SDT)
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed Categorization Task (RevCat)
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function scores
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition and motor function
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism risk
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function assessment
Number of subjects: 97
Study 36720262 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function
Number of subjects: 97
Study 36720290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare EMR (CS-EMR)
Number of subjects: 104
Study 36720290 — intervention group
Group type: COMPARATOR
Intervention: Conventional EMR with thermal ablation (EMR-T)
Number of subjects: 104
Study 36720425 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute loading (one bout of resistance exercise - one-legged leg press)
Number of subjects: 32
Study 36720425 — intervention group
Group type: COMPARATOR
Intervention: Control (no loading)
Number of subjects: 32
Study 36720560 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 204
Study 36720560 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study 36720570 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (5-fluorouracil, oxaliplatin, and irinotecan) for four cycles as neoadjuvant chemotherapy (NAC)
Number of subjects: 0
Study 36720576 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide once a week
Number of subjects: 104
Study 36720576 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a week
Number of subjects: 104
Study 36720731 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 10
Study 36720768 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs)
Number of subjects: 20
Study 36720768 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 20
Study 36720801 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-CT-guided strategy
Number of subjects: 0
Study 36720801 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Number of subjects: 0
Study 36720801 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (ICA and invasive pressure measurements)
Number of subjects: 0
Study 36721130 — intervention group
Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt implantation
Number of subjects: 124
Study 36721130 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 124
Study 36721135 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk Score (FINDRISC)
Number of subjects: 220
Study 36721135 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 220
Study 36721150 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing initiatives
Number of subjects: 28
Study 36721150 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of interviews
Number of subjects: 28
Study 36721157 — intervention group
Group type: EXPERIMENTAL
Intervention: L-GF injection
Number of subjects: 60
Study 36721157 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 60
Study 36721157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (L-GF and Control)
Number of subjects: 60
Study 36721174 — intervention group
Group type: EXPERIMENTAL
Intervention: HD201
Number of subjects: 502
Study 36721174 — intervention group
Group type: COMPARATOR
Intervention: Referent trastuzumab
Number of subjects: 502
Study 36721240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) samples from individuals with NPC1
Number of subjects: 0
Study 36721240 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF CALB2 levels
Number of subjects: 0
Study 36721240 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF CHI3L1 levels
Number of subjects: 0
Study 36721240 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF CCL18 levels
Number of subjects: 0
Study 36721372 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct methods of analyzing accelerated aging detrended for age as the outcome and controlling for age as a covariate (n = 16; 32%)
Number of subjects: 50
Study 36721372 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct methods of analyzing raw DNAm age as the outcome and controlling for age as a covariate (n = 5; 10%)
Number of subjects: 50
Study 36721372 — intervention group
Group type: COMPARATOR
Intervention: Incorrect method of analyzing accelerated aging detrended for age as the outcome without controlling for age as a covariate (n = 29; 58%)
Number of subjects: 50
Study 36721661 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 0
Study 36721661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36721920 — intervention group
Group type: EXPERIMENTAL
Intervention: 260 IU recombinant hCG (rhCG) daily injections for 8 weeks
Number of subjects: 20
Study 36721920 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no hCG priming)
Number of subjects: 20
Study 36721920 — intervention group
Group type: EXPERIMENTAL
Intervention: Study cycle (hCG priming)
Number of subjects: 20
Study 36721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled siR-7-EM/KK-46 (3.7 mg/day)
Number of subjects: 52
Study 36721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled siR-7-EM/KK-46 (11.1 mg/day)
Number of subjects: 52
Study 36721963 — intervention group
Group type: COMPARATOR
Intervention: Standard etiotropic drug treatment (control group)
Number of subjects: 52
Study 36722044 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP)
Number of subjects: 1070
Study 36722044 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 1070
Study 36722133 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir-velpatasvir
Number of subjects: 10
Study 36722133 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir-velpatasvir-voxilaprevir
Number of subjects: 10
Study 36722133 — intervention group
Group type: EXPERIMENTAL
Intervention: DAAs (direct-acting antivirals)
Number of subjects: 10
Study 36722133 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma viremia
Number of subjects: 10
Study 36722133 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-phase plasma dynamics
Number of subjects: 10
Study 36722147 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 (60 µg)
Number of subjects: 213
Study 36722147 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 (120 µg)
Number of subjects: 213
Study 36722147 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers vaccinated with RSVPreF3
Number of subjects: 213
Study 36722187 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening strategy using high-sensitivity cardiac troponin T (hs-cTnT) assay measured before surgery, and at the 2nd and 3rd days after surgery
Number of subjects: 1477
Study 36722187 — intervention group
Group type: COMPARATOR
Intervention: Usual care strategy
Number of subjects: 1477
Study 36722208 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 0
Study 36722208 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 0
Study 36722208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise
Number of subjects: 0
Study 36722208 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 0
Study 36722447 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 21
Study 36722463 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) parameters
Number of subjects: 366
Study 36722463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean heart rate
Number of subjects: 366
Study 36722630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group received three home visits by nurses one month after hospital discharge to provide stroke-related education and emotional support.
Number of subjects: 48
Study 36722630 — intervention group
Group type: COMPARATOR
Intervention: Control Group received the usual guidance from the health services.
Number of subjects: 48
Study 36723286 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (n=27)
Number of subjects: 42
Study 36723286 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 infection (n=15)
Number of subjects: 42
Study 36723286 — intervention group
Group type: COMPARATOR
Intervention: Comparison of biopsy findings (2019-2021)
Number of subjects: 42
Study 36723445 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36723678 — intervention group
Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel); chimeric antigen receptor T-cell therapy
Number of subjects: 229
Study 36723678 — intervention group
Group type: COMPARATOR
Intervention: SCHOLAR-5 external control cohort
Number of subjects: 229
Study 36723714 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal care (SPC)
Number of subjects: 108
Study 36723801 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer (individualized exercise and group education)
Number of subjects: 222
Study 36723880 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-in gamma probe
Number of subjects: 10
Study 36723880 — intervention group
Group type: COMPARATOR
Intervention: Rigid laparoscopic gamma probe (RLGP)
Number of subjects: 10
Study 36723892 — intervention group
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Number of subjects: 34
Study 36723892 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG
Number of subjects: 34
Study 36723911 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Irreversible Electroporation (IRE)
Number of subjects: 106
Study 36723911 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Irreversible Electroporation (IRE)
Number of subjects: 106
Study 36723913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab once weekly
Number of subjects: 209
Study 36723913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks
Number of subjects: 209
Study 36723913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant TCS once weekly
Number of subjects: 209
Study 36723913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant TCS every 2 weeks
Number of subjects: 209
Study 36723913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 36723919 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized accelerated pacing
Number of subjects: 107
Study 36723919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study 36723935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg or 20 mg)
Number of subjects: 441
Study 36723935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441
Study 36723935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 36723980 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP reconstruction
Number of subjects: 57
Study 36723980 — intervention group
Group type: COMPARATOR
Intervention: Brava expansion and fat grafting
Number of subjects: 57
Study 36723996 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture technique (CSG)
Number of subjects: 80
Study 36723996 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique (ISG)
Number of subjects: 80
Study 36723996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 36724001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single agent or combination therapy (inactive trials)
Number of subjects: 64
Study 36724001 — intervention group
Group type: COMPARATOR
Intervention: SARC006 trial (upfront chemotherapy in chemotherapy naïve patients)
Number of subjects: 64
Study 36724010 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (various functionalities including symptom diary, sleep time setting, alcohol tracker, exercise day setting, thought diary, goal setter)
Number of subjects: 50
Study 36724010 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention
Number of subjects: 50